753 results on '"Vassal G."'
Search Results
202. EPT-01DOSE-FINDING STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA: RESULTS OF THE ITCC/SIOPE-BRAIN VINILO PHASE I TRIAL (NCT01887522)
- Author
-
Grill J, Le Deley M, Le Teuff G, Abbou S, Geoerger B, Bautista-Sirvent F, Malekzadeh K, Paci A, De Carli E, Bertozzi A, Pagnier A, Doz F, Pierre LEBLOND, and Vassal G
203. EGFR inhibition using gefitinib is not active in neuroblastoma cell lines
- Author
-
Rössler, J., Odenthal, E. V. A., birgit geoerger, Gerstenmeyer, A., Lagodny, J., Niemeyer, C. M., and Vassal, G.
204. Gas chromatographic—mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard
- Author
-
Vassal, G., primary, Re, M., additional, and Gouyette, A., additional
- Published
- 1988
- Full Text
- View/download PDF
205. Differentiated Thyroid Carcinoma in Childhood: Long Term Follow-Up of 72 Patients
- Author
-
SCHLUMBERGER, M., primary, DE VATHAIRE, F., additional, TRAVAGLI, J. P., additional, VASSAL, G., additional, LEMERLE, J., additional, PARMENTIER, C., additional, and TUBIANA, M., additional
- Published
- 1987
- Full Text
- View/download PDF
206. RADIOSENSITISATION AFTER BUSULPHAN
- Author
-
Vassal, G., primary, Hartmann, O., additional, Habrand, J.L., additional, Pico, J.L., additional, and Lemerle, J., additional
- Published
- 1987
- Full Text
- View/download PDF
207. Energy dependence of defect energy levels in electron irradiated silicon
- Author
-
Krynicki, J., primary, Bourgoin, J.C., additional, and Vassal, G., additional
- Published
- 1979
- Full Text
- View/download PDF
208. Juvenile granulosa cell tumor of the ovary in children: a clinical study of 15 cases.
- Author
-
Vassal, G, primary, Flamant, F, additional, Caillaud, J M, additional, Demeocq, F, additional, Nihoul-Fekete, C, additional, and Lemerle, J, additional
- Published
- 1988
- Full Text
- View/download PDF
209. La protection des grands bobinages supraconducteurs
- Author
-
Bronca, G., primary, Krikorian, J., additional, Neel, J., additional, Vassal, G., additional, Burnier, P., additional, and Moreau, J., additional
- Published
- 1970
- Full Text
- View/download PDF
210. Camptothecin markedly enhances p53 transgene expression in human glioma cells after adenoviral-mediated gene transfer
- Author
-
Grill, J., Vassal, G., Haddada, H., Frebourg, T., May, E., and Feunteun, J.
- Subjects
Gene expression -- Physiological aspects -- Usage ,Gliomas -- Physiological aspects -- Usage ,Enzyme inhibitors -- Physiological aspects -- Usage ,Adenoviruses -- Usage -- Physiological aspects ,Health ,Physiological aspects ,Usage - Abstract
'Camptothecin Markedly Enhances p53 Transgene Expression in Human Glioma Cells after Adenoviral-Mediated Gene Transfer.' J. Grill, G. Vassal, H. Haddada, T. Frebourg, E. May and J. Feunteun. IGR and IRSC, [...]
- Published
- 1997
211. High-dose busulfan and thiotepa following radiation therapy in childhood malignant brain stem glioma
- Author
-
Kalifa, C., Hartmann, O., Vassal, G., Doz, F., Bouffet, E., Gentet, J.C., Demeocq, F., Chastagner, P., and Lutz, P.
- Subjects
Gliomas -- Care and treatment ,Cancer in children -- Care and treatment ,Busulfan -- Evaluation ,Thiotepa -- Evaluation ,Business ,Health care industry - Abstract
AUTHORS: C. Kalifa, O. Hartmann, G. Vassal, F. Doz, E. Bouffet, J.C. Gentet, F. Demeocq, P. Chastagner and P. Lutz. Department of Pediatrics, Institut Gustave Roussy, 94800 Villejuif, France, For [...]
- Published
- 1994
212. La biologie moléculaire des gliomes infiltrants du tronc de l’enfant : vers une thérapeutique ciblée ?
- Author
-
Puget, S., Philippe, C., Job, B., Varlet, P., Andreiuolo, F., Roujeau, T., Richon, C., Doz, F., Zerah, M., Blauwblomme, T., Sainte-Rose, C., Vassal, G., and Grill, J.
- Published
- 2011
- Full Text
- View/download PDF
213. Trajectoires scolaires après un cancer pédiatrique : une contribution à l’hypothèse de la sélection par la santé
- Author
-
Dumas, A., Berger, C., Auquier, P., Michel, G., Vassal, G., Valteau-Couanet, D., Fresneau, B., Thouvenin-Doulet, S., Casagranda, L., Pacquement, H., El-Fayech, C., Oberlin, O., Guibout, C., and De Vathaire, F.
- Abstract
Une santé dégradée pendant l’enfance ou l’adolescence, parce qu’elle peut avoir un impact sur la réussite scolaire ou les stratégies éducatives, peut réduire les chances de mobilité sociale et peut, par conséquent, contribuer à la formation des inégalités sociales de santé. Cependant, les études tendent à confondre les pathologies, rendant difficile l’exploration des mécanismes à l’œuvre. Nous proposons d’étudier ici le cas des cancers de l’enfant et de l’adolescent au travers d’une recherche à méthodes mixtes.
- Published
- 2016
- Full Text
- View/download PDF
214. 171 INVITED The European Network for Cancer Research in Children and Adolescents(ENCCA) FP7 Project
- Author
-
Ladenstein, R., Vassal, G., Pritchard-Jones, K., and Schrappe, M.
- Published
- 2011
- Full Text
- View/download PDF
215. 174 INVITED Spread of Excellence Activities of ENCCA
- Author
-
Vassal, G.
- Published
- 2011
- Full Text
- View/download PDF
216. 468P Real-world safety of trametinib monotherapy or in combination with dabrafenib in children, adolescents, and young adults with relapsed or refractory low-grade glioma (LGG) and high-grade glioma (HGG).
- Author
-
Taleb, N., Ndounga-Diakou, L.A., Abbou, S., Leblond, P., Aerts, I., Sevrin, F., Ducassou, S., André, N., Entz-Werle, N., Chastagner, P., Plantaz, D., Gambart, M., Puiseux, C., Khanfar, C., Thouvenin, S., Schneider, P., Vassal, G., Berlanga, P., and Laghouati, S.
- Subjects
- *
YOUNG adults , *GLIOMAS , *TEENAGERS - Published
- 2024
- Full Text
- View/download PDF
217. Transfert du gone p53 sauvage age dans une lignee humaine de carcinome epidermoide
- Author
-
Badie, C., Bourhis, J., Bosq, J., Haddada, H., Chiron, M., Virone, A., and Vassal, G.
- Published
- 1998
- Full Text
- View/download PDF
218. Operating characteristics of two independent sample design in phase I trials in paediatric oncology.
- Author
-
Raphaël M, le Deley M, Vassal G, and Paoletti X
- Abstract
PURPOSE: The European medicines agency (EMEA) has stated that the degree of pre-treatment could modify the patient's tolerance to new treatments in paediatric oncology. It is current practice to divide a phase I trial into two groups to identify the maximum tolerated dose (MTD) in each group separately. The aim of this study was to investigate the relevance of this approach. METHODS: We reanalysed a large phase I trial of Irinotecan that included 80 children (32 heavily pretreated patients and 48 less heavily pretreated). An extended simulation study was performed to investigate the robustness of the conclusions in the context of small sample sizes. Dose recommendations were studied according to scenarios with group differences, as measured by odds ratio (OR), ranging from 1 (no difference) to 10 (large difference) and sample sizes increasing from 20 x 2 to 60 x 2 patients. RESULTS: This study shows a high risk of misidentification of the MTD in each of the two groups, regardless of the group difference. With a group difference corresponding to OR=8 and balanced sample sizes (20 x 2 patients), the same MTD was identified in 11% of the simulations. Even with larger sample sizes (40 x 2 patients), this figure reached 24% for OR=3. There is also a very high risk of identifying two different MTD (52% for 40 x 2 patients) although the risk is similar in both groups. CONCLUSIONS: Two independent sample designs in paediatric phase I trials should be avoided or reserved to limited situations when there is a strong rationale possibly based on adult data. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
219. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy
- Author
-
Rubie, H., Doz, F., Vassal, G., Chastagner, P., Gentet, J-C., Urien, S., Bastian, G., Drouard-Troalen, L., Barberi-Heyob, M., Catalin, J., and Chatelut, E.
- Subjects
- *
ONCOLOGY , *BAYESIAN analysis - Abstract
Individual dosing of carboplatin based on drug monitoring was performed within a multi-centric phase I study based on high AUC-levels in children. Twelve patients (aged 3–17 years old) have been included: 3, 5, and 4 patients at the overall target ultrafilterable carboplatin AUC of 20, 25, or 30 mg/ml×min, respectively. Carboplatin was administered as a daily 60-min infusion, repeated on five consecutive days. The initial daily dose corresponding to the three first days was calculated according to the carboplatin clearance (CL) predicted from patients’ characteristics (body weight, serum creatinine and nephrectomy status). Three blood samples were taken per patient. The individual CL were estimated by MAP (maximum a posteriori approach) Bayesian method implemented in the MP-K program. The doses for day 4 and 5 was adjusted in order to obtain the overall target AUC. Drug monitoring led to a change in the carboplatin dose (overall administered dose versus overall dose planned) ranging from −41% to +45%. Pharmacokinetics were performed at day 5 for 7/12 children: mean relative change between day 1 and day 5 was −11% showing a statistically significant, but limited, decrease of CL from day 1 to day 5. The percentage of difference between the observed and target overall AUC ranged between −7% and +14%. Three patients (one at each AUC level) who were previously treated with cisplatin experienced dose-limiting hearing loss. In conclusion, drug monitoring and dose adjustment is needed for the control of carboplatin plasma exposure when administering high doses of carboplatin in children. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
220. Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy.
- Author
-
Cherbonnier, C, Déas, O, Vassal, G, Merlin, J L, Haeffner, A, Senik, A, Charpentier, B, Dürrbach, A, Bénard, J, and Hirsch, F
- Subjects
- *
CANCER chemotherapy , *GENETIC transformation , *TUMORS , *MYELOID leukemia , *ANTINEOPLASTIC antibiotics - Abstract
Chemotherapy remains the main tool for the treatment of cancers, but is often hampered by tumor cell resistance. In this context, the transfer of genes able to accentuate the effect of anticancer drugs may constitute a useful approach, as exemplified by inactivation of nuclear factor (NF)-κB via direct transfer of a gene encoding a negative dominant of its natural inhibitor IκB, leading to improved response to cancer chemotherapy. Following our previous report that transfection of human growth hormone (hGH) gene into human monocytic cell lines may also inactivate NF-κB in another situation, we decided to test the consequences of hGH gene transfer on cancer treatments. We demonstrated that hGH-transfected human myeloid leukemia U937 cells were sensitized to an apoptotic signal mediated by the anticancer drugs. In parallel, we found that, by inhibiting degradation of IκB, hGH gene transfer diminished NF-κB entry into the nuclei of U937 cells exposed to daunorubicin. Finally, we report that hGH-transfected tumor cells engrafted in nude mice responded in vivo to chemotherapy with nontoxic doses of daunorubicin whereas, under the same conditions, control tumor cells remained insensitive. Overall, this study therefore suggests that hGH gene transfer may offer new therapeutic prospects in cancer therapy. Cancer Gene Therapy (2002) 9, 497–504 doi:10.1038/sj.cgt.7700467 [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
221. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.
- Author
-
Valteau-Couanet, D, Benhamou, E, Vassal, G, Stambouli, F, Lapierre, V, Couanet, D, Lumbroso, J, and Hartmann, O
- Subjects
- *
NEUROBLASTOMA , *MYC oncogenes , *STEM cell transplantation - Abstract
Although infants with stage 4 neuroblastoma (NB) usually have a good prognosis, metastatic relapses after 1 year of age and amplification of the N-myc oncogene are established poor prognostic factors. In order to improve the survival of patients with such high-risk factors, we performed consolidation with a busulfan (600 mg/m2)-melphalan (140 mg/m2)-containing regimen followed by autologous stem cell transplantation (SCT). From 1986 to 1998, 12 patients were treated according to this strategy. Their median age at diagnosis was 9 months (1–11). Consolidation was performed after a metastatic relapse in five children, because of persistent bone metastases in one and as first-line consolidation in six patients whose tumor exhibited N-myc amplification. The 5-year EFS rate is 64.5% (36–85%) with a median follow-up of 92 months (20–126). One toxicity-related death occurred in a very heavily pretreated patient. Hepatic veno-occlusive disease was the major side-effect that occurred in nine of 12 children. This busulfan-melphalan combination appears to dramatically improve the prognosis of these high-risk infants with metastatic NB. Given its high toxicity, indications for this consolidation must be restricted to high-risk infants and a lower dose of busulfan (480 mg/m2) is recommended in children weighing less than 10 kg. Bone Marrow Transplantation (2000) 25, 937–942. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
222. P50 Joint Modelling of Intermediate Longitudinal Biomarkers to Predict Overall Survival in Patients with Solid Tumors.
- Author
-
Linsell, L., Paracha, N., Grossman, J., Bokemeyer, C., Garcia-Foncillas, J., Italiano, A., Vassal, G., Chen, Y., Torlinska, B., and Abrams, K.
- Subjects
- *
OVERALL survival , *FORECASTING , *TUMORS - Published
- 2023
- Full Text
- View/download PDF
223. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution.
- Author
-
Hartmann, O, Valteau-Couanet, D, Vassal, G, Lapierre, V, Brugières, L, Delgado, R, Couanet, D, Lumbroso, J, and Benhamou, E
- Subjects
- *
NEUROBLASTOMA , *PATIENTS , *DRUG therapy , *STEM cell transplantation - Abstract
The purpose of this paper is to study prognostic factors in neuroblastoma patients treated with high-dose chemotherapy and hematopoietic stem cell transplantation. Two hundred and eighteen children over 1 year of age and treated for stage 4 neuroblastoma were enrolled in this study. The median age at diagnosis was 39 months, the sex ratio 1.5 and 84% of patients had an abdominal primary tumor. Skeletal disease was detected in 79% of cases and bone marrow involvement in 93%. N-myc oncogene amplification was present in 27% of the patients studied. The probability of event-free survival at 5 years post-diagnosis was 29% in this series. Three major favorable prognostic factors were significant and independent in the multivariate analysis: age under 2 years at diagnosis (P < 0.01), absence of bone marrow metastases at diagnosis (P < 0.04) and the high-dose conditioning regimen containing busulfan–melphalan combination (P = 0.001). The quality of response to conventional primary chemotherapy was close to significance (P = 0.053). We conclude that factors related to the patient (age) and extent of disease are predictive of outcome in patients with neuroblastoma treated with conventional chemotherapy followed by surgical excision of the primary and consolidation with high-dose chemotherapy. They should be taken into account in future prospective studies. Moreover, the type of conditioning regimen appears to be the most important prognostic factor. This should encourage new investigations into innovative drug combinations. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
224. An academia-driven compassionate use program for patients with recurrent H3K27-altered diffuse midline glioma: a new way to access innovation when clinical trials are lacking.
- Author
-
Di Carlo, D., Annereau, M., Yoldjian, I., Vassal, G., and Grill, J.
- Subjects
- *
CLINICAL trials , *GLIOMAS - Published
- 2023
- Full Text
- View/download PDF
225. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
- Author
-
Minard-Colin, V., Auperir, A., Pillon, M., Burke, G. A. A., Barkauskas, D. A., Wheatley, K., Delgado, R. F., Alexander, S., Uyttebroeck, A., Bollard, C. M., Zsiros, J., Csoka, M., Kazanowska, B., Chiang, A. K., Miles, R. R., Wotherspoon, A., Adamson, P. C., Vassal, G., Patte, C., and Gross, T. G.
- Abstract
BACKGROUND Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in (children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. METHODS We conducted an open-label, international!, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes maiins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed. RESULTS Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitt's lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximab-chemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [Cl], 89.1 to 96.7) in the rituximab-chemotherapy group and 82.3% (95% Cl, 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer, 0.32; 95% Cl, 0.15 to 0.66; onesided P=0.00096, which reached the significance level required for this analysis). Eight patients in the rituximab-chemotherapy group died (4 deaths were diseaserelated, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatmentrelated) (hazard ratio, 0.36; 95% Cl, 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximabchemotherapy group and 24.2% in the chemotherapy group (P=0.G7); events were related mainly to febrile neutropenia and infection. Approximately twice as many patients in the rituximab-chemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion. CONCLUSIONS Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin's lymphoma and was associated with a higher incidence of hypogammaglobulinemia and, potentially, more episodes of infection. (Funded by the Clinical Research Hospital Program of the French Ministry of Health and others; ClinicalTrials.gov number, NCT01516580). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
226. Intercontinental collaboration in clinical trials for children and adolescents with cancer—A systematic review by ACCELERATE
- Author
-
Teresa Rojas, Andrew J. Pearson, Nicole Scobie, Leona Knox, Darshan Wariabharaj, Pamela Kearns, Gilles Vassal, Gregory Reaman, Todd Alonzo, Andrea Biondi, Kathy Brodeur‐Robb, Maryam Fouladi, Thomas Gross, Stephen Hunger, Geoff McCowage, Alberto Pappo, Martin Schrappe, Maria Grazia Valsecchi, Brenda Weigel, Peter Wejbora, James Whitlock, Michel Zwaan, Vickie Buenger, Donna Ludwinski, Elly Barry, Kathleen Neville, Anjali Sharma, Dominik Karres, de Rojas, T, Pearson, A, Scobie, N, Knox, L, Wariabharaj, D, Kearns, P, Vassal, G, Reaman, G, Alonzo, T, Biondi, A, Brodeur-Robb, K, Fouladi, M, Gross, T, Hunger, S, Mccowage, G, Pappo, A, Schrappe, M, Grazia Valsecchi, M, Weigel, B, Wejbora, P, Whitlock, J, Zwaan, M, Buenger, V, Ludwinski, D, Barry, E, Neville, K, Sharma, A, and Karres, D
- Subjects
Cancer Research ,medicine.medical_specialty ,Adolescent ,International Cooperation ,Adolescent cancer ,rare disease ,Neoplasms ,Pediatric oncology ,childhood cancer ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Child ,RC254-282 ,Research Articles ,clinical trials ,Clinical Trials as Topic ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Clinical Cancer Research ,rare diseases ,Cancer ,clinical trial ,medicine.disease ,drug development ,Therapeutic trial ,Pediatric cancer ,Clinical trial ,Clinical research ,clinical research ,Oncology ,Drug development ,Family medicine ,international collaboration ,adolescent cancer ,business ,Research Article - Abstract
Background Since pediatric cancer drug development is a global enterprise, we sought to provide an overview of the landscape of intercontinental clinical trials in pediatric oncology opened over the last decade. Methods ClinicalTrials.gov was systematically searched to identify all clinical therapeutic trials which opened between 2010 and 2020 and recruited pediatric patients (, Intercontinental collaboration is alarmingly rare in childhood cancer trials, despite the rare disease setting and despite pediatric clinical research being inevitably a global enterprise. Barriers to collaboration should be identified and met with specific solutions to accelerate urgently needed drug development for children and adolescents with cancer.
- Published
- 2021
227. 464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset.
- Author
-
Italiano, A., Drilon, A.E., Shen, L., Hong, D.S., van Tilburg, C., Tan, D.S.W., Lin, J.J., Kummar, S., Doz, F., Geoerger, B., Brose, M.S., Briggs, A., Lassen, U.N., Vassal, G., Keating, K.N., Norenberg, R., Dima, L., Brega, N., Laetsch, T., and Garcia-Foncillas, J.
- Subjects
- *
TROPOMYOSINS , *CLINICAL trials - Published
- 2022
- Full Text
- View/download PDF
228. An academia-driven compassionate use program for patients with recurrent H3K27-altered diffuse midline glioma: a new way to access innovation when clinical trials are lacking
- Author
-
Di Carlo, D., Annereau, M., Yoldjian, I., Vassal, G., and Grill, J.
- Full Text
- View/download PDF
229. Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors
- Author
-
Daniel Orbach, Maura Massimino, Ewa Bien, Annalisa Trama, Gianni Bisogno, Gilles Vassal, Gemma Gatta, Pamela Kearns, Ines B Brecht, Michael C. Ost, Yves Reguerre, Teresa Stachowicz-Stencel, Jan Godzinski, Chiara Magni, Giovanni Cecchetto, Andrea Ferrari, Dominik T. Schneider, Andrea Biondi, Ferrari, A, Brecht, I, Gatta, G, Schneider, D, Orbach, D, Cecchetto, G, Godzinski, J, Reguerre, Y, Bien, E, Stachowicz-Stencel, T, Ost, M, Magni, C, Kearns, P, Vassal, G, Massimino, M, Biondi, A, Bisogno, G, and Trama, A
- Subjects
0301 basic medicine ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Consensus ,Adolescent ,Cancer registrie ,Cancer registries ,Incidence ,Very rare paediatric cancers ,Oncology ,Population ,Consensu ,Listing (computer) ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Neoplasms ,Humans ,Medicine ,media_common.cataloged_instance ,Registries ,Paediatric age ,European union ,Child ,education ,media_common ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Cancer ,Very rare paediatric cancer ,medicine.disease ,Europe ,Joint action ,030104 developmental biology ,030220 oncology & carcinogenesis ,business ,International Classification of Diseases for Oncology - Abstract
Although all tumours are rare in childhood, there are some particularly rare paediatric cancers which have not benefited from advances made by the international paediatric oncology network. To establish a shared definition and produce a list of these entities, the European Union Joint Action on Rare Cancers (JARC) promoted a consensus effort. The definition was based on the incidence rates estimated using the information network on rare cancers (RARECAREnet) database, pooling data from 94 population-based cancer registries and 27 countries. The RARECAREnet list of cancers was used to estimate the incidence rates. This list groups cancers by combining the International Classification of Diseases for Oncology, third edition, morphology and topography codes. According to the consensus, very rare paediatric cancers were identified as those with an annual incidence 2/1000000 (i.e. thyroid and testicular cancers and skin melanoma), but the consensus experts considered them as ‘very rare’ according to their clinical needs (e.g. shortage of knowledge and clinical expertise as the other rare paediatric cancers). The JARC consensus produced a definition and a list of very rare paediatric cancers which may represent a starting point for prioritising research on these tumours, based on data and patients’ clinical needs.
- Published
- 2019
230. 061 - INTER-B NHL-RITUX-2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-NHL: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY.
- Author
-
Minard-Colin, V., Aupérin, A., Burke, A., Alexander, S., Moreno, M., Buffardi, S., Uyttebroeck, A., Bollard, C., Zsiros, J., Csoka, M., Kazanowska, B., Chiang, A., Verschuur, A., Miles, R., Wotherspoon, A., Barkauskas, D., Wheatley, K., Vassal, G., Adamson, P., and Gross, T.
- Subjects
- *
PATIENT safety , *RITUXIMAB , *TEENAGERS , *CANCER chemotherapy - Published
- 2022
- Full Text
- View/download PDF
231. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
- Author
-
Geeta G. Sharma, Sorcha Forde, Hélène Pacquement, Ivonne A. Montes-Mojarro, Ralf Jauch, Wolfram Klapper, Cosimo Lobello, Liam C. Lee, Luca Mologni, Anne Lambilliotte, Suzanne D. Turner, Laurence Brugières, Roberto Chiarle, Stephen P. Ducray, Jamie D. Matthews, Birgit Geoerger, Shahid Pervez, Carlo Gambacorti-Passerini, Lukas Kenner, Šárka Pospíšilová, Klaas Bahnsen, Shi-Lu Luan, Nina Prokoph, Andrea Janíková, G. A. Amos Burke, Olaf Merkel, Huan-Chang Liang, Elif Karaca-Atabay, Hugo Larose, Wilhelm Woessmann, Qi Wang, Andishe Attarbaschi, Jack M. Monahan, Vikas Malik, Judith Landman-Parker, Isaia Barbieri, Gilles Vassal, Gudrun Schleiermacher, Nicola A. Probst, Matthews, Jamie [0000-0002-2980-8615], Larose, Hugo [0000-0003-4678-6048], Barbieri, Isaia [0000-0003-3035-8970], Turner, Suzanne [0000-0002-8439-4507], Apollo - University of Cambridge Repository, Prokoph, N, Probst, N, Lee, L, Monahan, J, Matthews, J, Liang, H, Bahnsen, K, Montes-Mojarro, I, Karaca-Atabay, E, Sharma, G, Malik, V, Larose, H, Forde, S, Ducray, S, Lobello, C, Wang, Q, Luan, S, Pospisilova, S, Gambacorti Passerini, C, Burke, G, Pervez, S, Attarbaschi, A, Janikova, A, Pacquement, H, Landman-Parker, J, Lambilliotte, A, Schleiermacher, G, Klapper, W, Jauch, R, Woessmann, W, Vassal, G, Kenner, L, Merkel, O, Mologni, L, Chiarle, R, Brugieres, L, Geoerger, B, Barbieri, I, and Turner, S
- Subjects
0301 basic medicine ,STAT3 Transcription Factor ,NPM1 ,medicine.drug_class ,Immunology ,Interleukin-10 Receptor alpha Subunit ,Gene Expression ,Antineoplastic Agents ,Biochemistry ,Models, Biological ,Interleukin 10 receptor, alpha subunit ,Cell Line ,03 medical and health sciences ,0302 clinical medicine ,Crizotinib ,hemic and lymphatic diseases ,medicine ,Anaplastic lymphoma kinase ,Humans ,Anaplastic large-cell lymphoma ,Protein Kinase Inhibitors ,Gene Editing ,Dose-Response Relationship, Drug ,business.industry ,Cancer ,Cell Biology ,Hematology ,Protein-Tyrosine Kinases ,medicine.disease ,Chemotherapy regimen ,Immunohistochemistry ,ALK inhibitor ,030104 developmental biology ,Drug Resistance, Neoplasm ,Cancer research ,Lymphoma, Large-Cell, Anaplastic ,IL10 ALK ,CRISPR-Cas Systems ,business ,Nucleophosmin ,030215 immunology ,medicine.drug ,Signal Transduction - Abstract
Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by nucleophosmin 1 (NPM1)-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54% to 90% in clinical trials; however, a subset of patients progressed within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) activation and knockout screens in ALCL cell lines, combined with RNA sequencing data derived from ALK inhibitor–relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of interleukin 10 receptor subunit alpha (IL10RA). Elevated IL10RA expression rewires the STAT3 signaling pathway, bypassing otherwise critical phosphorylation by NPM1-ALK. IL-10RA expression does not correlate with response to standard chemotherapy in pediatric patients, suggesting that a combination of crizotinib and chemotherapy could prevent ALK inhibitor resistance–specific relapse.
- Published
- 2020
232. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
- Author
-
Moreno, Lucas, Barone, Giuseppe, DuBois, Steven G, Molenaar, Jan, Fischer, Matthias, Schulte, Johannes, Eggert, Angelika, Schleiermacher, Gudrun, Speleman, Frank, Chesler, Louis, Geoerger, Birgit, Hogarty, Michael D, Irwin, Meredith S, Bird, Nick, Blanchard, Guy B, Buckland, Sean, Caron, Hubert, Davis, Susan, De Wilde, Bram, Deubzer, Hedwig E, Dolman, Emmy, Eilers, Martin, George, Rani E, George, Sally, Jaroslav, Štěrba, Maris, John M, Marshall, Lynley, Merchant, Melinda, Mortimer, Peter, Owens, Cormac, Philpott, Anna, Poon, Evon, Shay, Jerry W, Tonelli, Roberto, Valteau-Couanet, Dominique, Vassal, Gilles, Park, Julie R, Pearson, Andrew D J, UU BETA RESEARCH, Blanchard, Guy [0000-0002-3689-0522], Philpott, Anna [0000-0003-3789-2463], Apollo - University of Cambridge Repository, UU BETA RESEARCH, Moreno L., Barone G., DuBois S.G., Molenaar J., Fischer M., Schulte J., Eggert A., Schleiermacher G., Speleman F., Chesler L., Geoerger B., Hogarty M.D., Irwin M.S., Bird N., Blanchard G.B., Buckland S., Caron H., Davis S., De Wilde B., Deubzer H.E., Dolman E., Eilers M., George R.E., George S., Jaroslav, Maris J.M., Marshall L., Merchant M., Mortimer P., Owens C., Philpott A., Poon E., Shay J.W., Tonelli R., Valteau-Couanet D., Vassal G., Park J.R., and Pearson A.D.J.
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Drug development ,Antineoplastic Agents ,Medical Oncology ,Pediatrics ,03 medical and health sciences ,Neuroblastoma ,0302 clinical medicine ,Clinical trials ,Phase I ,Drug Development ,Internal medicine ,MYCN ,Drug Discovery ,medicine ,Anaplastic lymphoma kinase ,Humans ,Molecular Targeted Therapy ,Child ,Protein Kinase Inhibitors ,ATRX ,Drug discovery ,business.industry ,Paediatric oncology ,Brain Neoplasms ,Therapies, Investigational ,Epigenetic ,Cancer ,Preclinical testing ,Congresses as Topic ,medicine.disease ,3. Good health ,Clinical trial ,Europe ,030104 developmental biology ,030220 oncology & carcinogenesis ,Epigenetics ,business - Abstract
Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012 to accelerate the development of new drugs for neuroblastoma. Advances have occurred, with eight of nine high-priority targets being evaluated in paediatric trials including anaplastic lymphoma kinase inhibitors being investigated in front-line, but significant challenges remain. This article reports the conclusions of the second NDDS forum, which expanded across the Atlantic to further develop the initiative. Pre-clinical and clinical data for 40 genetic targets and mechanisms of action were prioritised and drugs were identified for early-phase trials. Strategies to develop drugs targeting TERT, telomere maintenance, ATRX, alternative lengthening of telomeres (ALT), BRIP1 and RRM2 as well as direct targeting of MYCN are high priority and should be championed for drug discovery. Promising pre-clinical data suggest that targeting of ALT by ATM or PARP inhibition may be potential strategies. Drugs targeting CDK2/9, CDK7, ATR and telomere maintenance should enter paediatric clinical development rapidly. Optimising the response to anti-GD2 by combinations with chemotherapy, targeted agents and other immunological targets are crucial. Delivering this strategy in the face of small patient cohorts, genomically defined subpopulations and a large number of permutations of combination trials, demands even greater international collaboration. In conclusion, the NDDS provides an internationally agreed, biologically driven selection of prioritised genetic targets and drugs. Improvements in the strategy for conducting trials in neuroblastoma will accelerate bringing these new drugs more rapidly to front-line therapy. (C) 2020 Elsevier Ltd. All rights reserved.
- Published
- 2020
233. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium
- Author
-
Nicolas U. Gerber, Maria Giuseppina Cefalo, Guy Makin, Antonio Juan Ribelles, Nicolas André, Manuel Diezi, Teresa de Rojas, Franca Fagioli, Francisco Bautista, Carmelo Rizzari, Claudia Rossig, Ingrid Øra, Christine Rawlings, Antonio Ruggiero, Pilar Guerra-García, Simone Hettmer, Stéphane Ducassou, Raquel Hladun, Gilles Vassal, Marion Gambart, Birgit Geoerger, Alba Rubio-San-Simón, Ben Carpenter, Karsten Nysom, Lynley V. Marshall, Natasha K. A. van Eijkelenburg, Marion Strullu, Sarah Benezech, Bram De Wilde, Isabelle Aerts, Jaime Verdú, Torben Ek, Cormac Owens, Sauli Palmu, Lucas Moreno, Luca Bergamaschi, Alicia Castañeda, Rubio San Simón, A, André, N, Cefalo, M, Aerts, I, Castañeda, A, Benezech, S, Makin, G, van Eijkelenburg, N, Nysom, K, Marshall, L, Gambart, M, Hladun, R, Rossig, C, Bergamaschi, L, Fagioli, F, Carpenter, B, Ducassou, S, Owens, C, Øra, I, Ribelles, A, De Wilde, B, Guerra García, P, Strullu, M, Rizzari, C, Ek, T, Hettmer, S, Gerber, N, Rawlings, C, Diezi, M, Palmu, S, Ruggiero, A, Verdú, J, de Rojas, T, Vassal, G, Geoerger, B, Moreno, L, and Bautista, F
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Paediatric haematology and oncology ,0302 clinical medicine ,Clinical trials ,Neoplasms ,Surveys and Questionnaires ,Pandemic ,Epidemiology ,Child ,Original Research ,Clinical Trials, Phase I as Topic ,Health Policy ,Clinical trial ,Europe ,Oncology ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,030220 oncology & carcinogenesis ,Preparedness ,Healthcare policy ,Female ,COVID-19 ,medicine.medical_specialty ,Drug development ,Phase I as Topic ,03 medical and health sciences ,Clinical Trials, Phase II as Topic ,medicine ,Humans ,Pandemics ,Health policy ,business.industry ,SARS-CoV-2 ,Phase II as Topic ,Cancer ,medicine.disease ,COVID-19, Clinical trials, Drug development, Healthcare policy, Paediatric haematology and oncology ,Patient recruitment ,Drug Development ,030104 developmental biology ,Clinical research ,Family medicine ,business - Abstract
Introduction Data regarding real-world impact on cancer clinical research during COVID-19 are scarce. We analysed the impact of the COVID-19 pandemic on the conduct of paediatric cancer phase I-II trials in Europe through the experience of the Innovative Therapies for Children with Cancer (ITCC). Methods A survey was sent to all ITCC-accredited Early-Phase Clinical Trial Hospitals including questions about impact on staff activities, recruitment, patient care, supply of investigational products and legal aspects, between 1/March and 30/April/2020. Results Thirty-one out of 53 hospitals from 12 countries participated. Challenges reported included staff constraints (30% drop), reduction in planned monitoring activity (67% drop of site initiation visits and 64% of monitoring visits) and patient recruitment (61% drop compared to 2019). The percentage of phase I, phase II trials and molecular platforms closing to recruitment in at least one site was 48.5%, 61.3% and 64.3%, respectively. Additionally, 26% of sites had restrictions on performing trial assessments due to local contingency plans. Almost half of the units suffered impact upon pending contracts. Most hospitals (65%) are planning on improving organizational and structural changes. Conclusion The study reveals a profound disruption of paediatric cancer early phase clinical research due to the COVID-19 pandemic across Europe. Reported difficulties affected both patient care and monitoring activity. Efforts should be made to reallocate resources to avoid lost opportunities for patients and to allow the continued advancement of oncology research. Identified adaptations to clinical trial procedures may be integrated to increase preparedness of clinical research to futures crises., Highlights • The COVID-19 pandemic has profoundly disrupted paediatric cancer clinical research. • A drastic drop in recruitment in phase I/II trials compared to 2019 was observed. • Current research needs reorganization to avoid loss of opportunities for children.
- Published
- 2020
234. 347 Efficacy of Dasatinib in Targeting Diffuse Intrinsic Pontine Glioma (DIPG) Specific Pathway Activation in Vitro
- Author
-
Truffaux, N., Puget, S., Vassal, G., Geoerger, B., and Grill, J.
- Published
- 2012
- Full Text
- View/download PDF
235. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
- Author
-
Veal, G.J., Nguyen, L., Paci, A., Riggi, M., Amiel, M., Valteau-Couanet, D., Brock, P., Ladenstein, R., and Vassal, G.
- Subjects
- *
BLOOD testing , *ANTINEOPLASTIC agents , *CANCER chemotherapy , *TUMORS in children , *DESCRIPTIVE statistics , *CHILDREN - Abstract
Abstract: Introduction: Busulfan is widely used in a neuroblastoma setting, with several studies reporting marked inter-patient variability in busulfan pharmacokinetics and pharmacodynamics. The current study reports on the pharmacokinetics of oral versus intravenous (IV) busulfan in high-risk neuroblastoma patients treated on the European HR-NBL-1/SIOPEN study. Methods: Busulfan was administered four times daily for 4days to children aged 0.7–13.1years, either orally (1.45–1.55mg/kg) or by the IV route (0.8–1.2mg/kg according to body weight strata). Blood samples were obtained prior to administration, 2, 4, and 6h after the start of administration on dose 1. Busulfan analysis was carried out by gas chromatography–mass spectrometry and data analysed using a NONMEM population pharmacokinetic approach. Results: Busulfan plasma concentrations obtained from 38 patients receiving IV busulfan and 25 patients receiving oral busulfan, were fitted simultaneously using a one-compartment pharmacokinetic model. Lower variability in drug exposure was observed following IV administration, with a mean busulfan area under the plasma concentration versus time curve (AUC) of 1146±187μM.min (range 838–1622), as compared to 953±290μM.min (range 434–1427) following oral busulfan. A total of 87% of children treated with IV busulfan achieved AUC values within the target of 900–1500μM.min versus 56% of patients following oral busulfan. Busulfan AUC values were significantly higher in HR-NBL-1/SIOPEN trial patients who experienced hepatic toxicity or veno-occlusive disease (VOD) (1177±189μM.min versus 913±256μM.min; p =0.0086). Further stratification based on route of administration suggested that the incidence of hepatic toxicity was related to both high busulfan AUC and oral drug administration. Conclusion: The reduced pharmacokinetic variability and improved control of busulfan AUC observed following IV administration support its utility within the ongoing HR-NBL-1/SIOPEN trial. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
236. Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework
- Author
-
Doussau, A., Asselain, B., Le Deley, M.C., Geoerger, B., Doz, F., Vassal, G., and Paoletti, X.
- Subjects
- *
PEDIATRICS , *CLINICAL trials , *COMPARATIVE studies , *ONCOLOGY research , *TUMORS in children , *DOSE-effect relationship in pharmacology - Abstract
Abstract: Objective: Usual dose-finding methods in oncology are sequential. Accrual is suspended after each group of patients to assess toxicity before increasing the dose. An adapted Continual Reassessment Method (CRM) and Rolling 6 (R6) method, designed to avoid this suspension of accrual in pediatric oncology, are compared with the traditional 3+3 design. Study design and setting: The competing performances were evaluated in a simulation study integrating the temporal dimension, and a phase I trial was reanalyzed. We compared methods for various interpatient arrival times and dose-toxicity relations, in terms of distribution of final recommendations, number of skipped children and duration of trials. Results: R6 and CRM can be safely implemented to limit trial suspensions, especially when mean interpatient arrival time is short. CRM was found to be more efficient than algorithm-based methods (44% of good recommendations vs. 38%) but moderately increased the risk of overtreatment. The R6 design included more patients at suboptimal doses. The design with the shortest study duration depended on the number of dose to escalate before the target. Conclusion: These new methods can reduce the number of skipped patients, but only provide limited gain in terms of ability to select the right dose. New designs are needed. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
237. The state of research into children with cancer across Europe: new policies for a new decade.
- Author
-
Pritchard-Jones, K., Lewison, G., Camporesi, S., Vassal, G., Ladenstein, R., Benoit, Y., Predojevic, J. S., Sterba, J., Stary, J., Eckschlager, T., Schroeder, H., Doz, F., Creutzig, U., Klingebiel, T., Kosmidis, H. V., Garami, M., Pieters, R., O'Meara, A., Dini, G., and Riccardi, R.
- Subjects
- *
CHILDHOOD cancer , *TUMORS in children , *HEALTH policy , *CHILDREN'S health , *MEDICAL communication , *ETIOLOGY of diseases - Abstract
Overcoming childhood cancers is critically dependent on the state of research. Understanding how, with whom and what the research community is doing with childhood cancers is essential for ensuring the evidence-based policies at national and European level to support children, their families and researchers. As part of the European Union funded EUROCANCERCOMS project to study and integrate cancer communications across Europe, we have carried out new research into the state of research in childhood cancers. We are very grateful for all the support we have received from colleagues in the European paediatric oncology community, and in particular from Edel Fitzgerald and Samira Essiaf from the SIOP Europe office. This report and the evidence-based policies that arise from it come at a important junction for Europe and its Member States. They provide a timely reminder that research into childhood cancers is critical and needs sustainable long-term support. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
238. 542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.
- Author
-
Italiano, A., Hong, D.S., Briggs, A., Garcia-Foncillas, J., Lassen, U.N., Vassal, G., Kummar, S., van Tilburg, C.M., Keating, K., Reeves, J.A., Fellous, M., Nogai, H., Laetsch, T.W., and Drilon, A.
- Subjects
- *
CANCER patients - Published
- 2020
- Full Text
- View/download PDF
239. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
- Author
-
Calvet, L., Geoerger, B., Regairaz, M., Opolon, P., Machet, L., Morizet, J., Joseph, J.-M., Elie, N., and Vassal, G.
- Subjects
- *
NEUROBLASTOMA , *NATURAL immunity , *NEOVASCULARIZATION , *THERAPEUTICS , *GENE expression , *XENOGRAFTS - Abstract
In vivo neuroblastoma (NB) xenograft model, resistant to the DNA-topoisomerase I inhibitor irinotecan (CPT-11), has been established to study resistance mechanisms acquired in a therapeutic setting. Common mechanisms of resistance were not involved in this resistance. Thus, we compared the gene expression profiles of sensitive, resistant, and reverted tumors using cDNA expression arrays. Expression of selected transcripts was confirmed by quantitative real-time PCR. We found that pleiotrophin (PTN), a heparin-binding growth factor, was the only gene significantly affected: PTN gene expression was downregulated in all resistant tumors (8–14-fold) as compared to sensitive tumors, and was increased (2–4-fold) in all reverted tumors as compared to resistant tumors. PTN thus appeared to be a likely candidate gene associated with resistance to CPT-11 in this in vivo model. To investigate the direct implication of PTN in NB, we transfected two NB cell lines with RNA interferences in order to silence PTN. PTN failed to demonstrate implication in resistance to CPT-11 in vitro but could influence sensitivity to CPT-11 exclusively through an in vivo mechanism. Indeed, vasculature was significantly enhanced in resistant NB xenografts compared to sensitive and reverted xenografts, and we suggest that PTN is acting in our resistant in vivo NB model as an angiostatic factor.Oncogene (2006) 25, 3150–3159. doi:10.1038/sj.onc.1209348; published online 27 February 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
240. Thérapies ciblées en oncologie pédiatrique : nouvelle approche thérapeutique
- Author
-
Jubert, C., Geoerger, B., Grill, J., Hartmann, O., and Vassal, G.
- Subjects
- *
CHILDHOOD cancer , *TUMORS in children , *CANCER treatment , *THERAPEUTICS , *CANCER cells , *TUMOR treatment - Abstract
Abstract: A multidisciplinary therapeutic approach has led to significant increase in survival of children with cancer, however often with a high rate of severe sequela. Better understanding in tumor cell biology and transformation process allowed to describe active tyrosine kinases (mainly growth factor receptors) as a new target for cancer treatment. This review presents 2 approaches to target receptor tyrosine kinase activity: on one hand, antibodies that target the extracellular domain, the natural ligand binding site, and on the other hand, small inhibiting molecules, such as imatinib, targeted against the activated intracellular receptor tyrosine kinase. We focus on their clinical development and current application in the treatment of childhood cancer. Targeted therapies are in full rise and new perspectives are explored, such as their association to other treatment modalities and the targeting of microenvironment. This new therapeutic approach necessitates well designed clinical trials that include relevant biomarkers to evaluate its real therapeutic potential. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
241. European collaboration in trials of new agents for children with cancer
- Author
-
Ablett, S., Doz, F., Morland, B., and Vassal, G.
- Subjects
- *
CHILDHOOD cancer , *CANCER , *CLINICAL trials - Abstract
Childhood cancer is a relatively rare disease, representing just 1% of all malignancies. Within Europe, this represents some 12,000 new cases each year, with approximately 1600 a year in the United Kingdom and 1800 in France. International collaboration in phase III trials of childhood cancer has been the norm for many years, traditionally within Europe, but, largely because of organisational considerations, phase I and II trials have only been conducted on a national basis. With overall cure rates in the region of 70%, relatively few children are available for these early drug trials. Access to new drugs is also a major problem. Against this background, a United Kingdom (UK)/French `new agent'' collaboration was established, expanding subsequently into a wider European grouping. This paper documents the history of that collaboration, the outcomes and future challenges. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
242. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
- Author
-
Bouligand, J, Boland, I, Valteau-Couanet, D, Deroussent, A, Kalifa, C, Hartmann, O, and Vassal, G
- Subjects
- *
ALKYLATING agents , *PHARMACODYNAMICS , *STEM cell transplantation , *ANTINEOPLASTIC agents , *MEDULLOBLASTOMA - Abstract
Summary:A strong relationship has been demonstrated between high systemic exposure to busulfan and the occurrence of hepatic veno-occlusive disease (HVOD) after a busulfan-cyclophosphamide regimen (BU CY). We report a prospective study aimed at exploring the pharmacodynamics of high-dose busulfan combined with either melphalan (BU MEL) or thiotepa (BU TTP) followed by autologous stem cell transplantation in children and adolescents with a malignant solid tumor. Busulfan was given orally at a total dose of 600?mg?m-2. In all, 45 patients with a median age of 6.3 years were included in the study: 25 received BU MEL and 20 received BU TTP. The incidence of HVOD was 44% (CI 95% [23-65%]) in the BU MEL group and 25% (CI95% [9-49%]) in the BU TTP group. In the BU TTP group, patients who developed HVOD had a significantly higher AUC 0-6?h after the 13th dose (6201±607?h?ng?ml-1) than those who did not (5024±978?h?ng?ml-1) (P<0.05). In the BU MEL group, there was no difference in terms of systemic exposure to busulfan between patients who developed HVOD and those who did not. In conclusion, the guidelines established for monitoring BU CY cannot be extrapolated when busulfan is combined with another drug.Bone Marrow Transplantation (2003) 32, 979-986. doi:10.1038/sj.bmt.1704275 [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
243. Statutory pediatric informations available for anticancer drugs : inventory and proposals.
- Author
-
Thouvenel, C., Gény, M.S., Demirdjian, S., and Vassal, G.
- Subjects
- *
PEDIATRIC pharmacology , *TUMORS in children , *ANTINEOPLASTIC agents , *PEDIATRIC drug therapy , *ANTINEOPLASTIC antibiotics - Abstract
Paediatric medicines are often prescribed off label because appropriate clinical and pharmacological studies have not been conducted in children. A European directive is being written to promote the development of paediatric medicines through incentives to pharmaceutical companies, as is already the case in the US.Method. – In order to evaluate the status of anticancer drugs, we analyzed the paediatric information available in the Vidal® 2000 dictionary for cytotoxic chemotherapy.Results. – Among the 76 products, 48 were currently used to treat children with cancer. An indication for paediatric use was described in only 29% of them. Paediatric use was mentioned in the posology chapter in 56% of cases, and in the warning or contra-indication chapter in 17% of cases. Ten products (21%) were devoid of paediatric information.Discussion. – The paucity of this official paediatric information contrasts with the number of clinical and pharmacological studies that have been conducted and published by paediatric oncology societies and groups. Indeed, almost 80% of children with cancer are treated using prospective therapeutic research protocols. In conclusion, anticancer medicines have been evaluated in children, but official paediatric information is poor. This situation can be significantly improved with the literature currently available. On the other hand, prospective clinical studies are needed to better define the optimal dose in children under one year of age, to evaluate long-term sequelae in cured patients and to provide appropriate galenic forms for oral chemotherapy.Conclusion. – Incentives are urgently needed to facilitate access to therapeutic innovations in oncology and their development in children with cancer. [Copyright &y& Elsevier]
- Published
- 2002
244. A European paediatric cancer mission: aspiration or reality?
- Author
-
Olga Kozhaeva, Angelika Eggert, Anita Kienesberger, Gilles Vassal, Kjeld Schmiegelow, Patricia Blanc, Pamela Kearns, Andrea Biondi, Ruth Ladenstein, Martin Schrappe, Rob Pieters, Kearns, P, Vassal, G, Ladenstein, R, Schrappe, M, Biondi, A, Blanc, P, Eggert, A, Kienesberger, A, Kozhaeva, O, Pieters, R, and Schmiegelow, K
- Subjects
medicine.medical_specialty ,business.industry ,MEDLINE ,World Health Organization ,Pediatrics ,paediatric cancer mission ,Europe ,Oncology ,Paediatric cancer ,Child, Preschool ,Neoplasms ,medicine ,Humans ,Intensive care medicine ,business ,Child - Published
- 2019
245. Xenograpted medulloblastomas: Cytogenetic and FISH analysis
- Author
-
Vénuat, AM, Vassal, G, Terrier-lacombe, MJ., Kalifa, C, Gouyette, A, and Bernheim, A
- Published
- 1994
- Full Text
- View/download PDF
246. Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.
- Author
-
Karayan-Tapon, L., Cortes, U., Rivet, P., Jermidi, C., Vassal, G., Wager, M., and Taillandier, L.
- Subjects
- *
GLIOMAS - Published
- 2014
- Full Text
- View/download PDF
247. 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer.
- Author
-
Leyvraz, S., Yang, J.C-H., Casali, P.G., Castro, G., Kim, E.S., Lassen, U.N., Lopez-Rios, F., Penault-Llorca, F., Pappo, A., Rudzinski, E.R., Tabatabai, G., Vassal, G., Reeves, J.A., Nogai, H., Fellous, M., Drilon, A., Brose, M.S., and Trent, J.
- Subjects
- *
PATIENTS - Published
- 2020
- Full Text
- View/download PDF
248. 364OClinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC.
- Author
-
Mezquita, L, Planchard, D, Suarez, M Dorta, Aldea, M, Naltet, C, Lamberts, V, Grecea, M, Martin-Romano, P, Kievit, F de, Jovelet, C, Lacroix, L, Masip, J Remon, Lavaud, P, Gazzah, A, Morris, C, Howarth, K, Green, E, Vassal, G, Massard, C, and Besse, B
- Subjects
- *
STOCK options , *RESEARCH grants , *NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptors - Abstract
Background The comprehensive genomic profile (CGP) by next generation sequencing (NGS) ctDNA can identify a wide spectrum of GA that range from drivers with approved targeted therapies for routine use to other GA with lack of evidence for actionability. We aimed to assess the clinical utility of NGS-ctDNA based on ESCAT in a large cohort of NSCLC patients. Methods Advanced NSCLC patients were prospectively enrolled between 11.2015-05.2019 in the Liquid Biopsy Program in our institution. Plasma ctDNA was collected at diagnosis, under therapy or at progressive disease (PD) and analyzed by InVisionFirstTMLung. We evaluated the detection of driver GA on ctDNA and the clinical utility for accessing targeted therapies approved for routine use (EGFR mutation (m), ALK rearrangement (r), BRAFV600Em, ROS1r), according to ESCAT tiers. Results Preliminary results are available for 308 patients/547 samples (n = 117 untreated; 217 at PD). 58% were females, 42% nonsmokers, with median age of 61 (24-90) and 87% had adenocarcinoma. At diagnosis, ≥1 ctDNA GA was found in 79% (91/115; 2 failed analyses): 29% (26/91) were ESCAT tier I (16 EGFRm ex19/21, 1 ALKr, 1 ROS1r, 8 BRAFV600Em), 2% ESCAT tier II (2 METa ; 1 case co-driver with EGFRm) and 31% tier III (21 KRASm with 8 cases G12C; 5 HER2m, 2EGFRm ex20). ctDNA provided clinically informative results for 33% (38/115). At PD, ≥1 ctDNA GA was found in 75% (163/217); 2 failed analyses): 65% (106/163) in ESCAT tier I (66 EGFRm ex19/21, 7 ALKr, 32 BRAFV600Em, 1 ROS1r), <1% ESCAT tier II (1 METa) and 18% tier III (16 KRASm with 10 cases G12C; 10 HER2m, 3 EGFR others). ctDNA provided clinically informative results for 60% (130/217). We detected EGFR T790M in 49% (17/35) after 1st-2nd generation TKI, C797Sm in 75% (3/4) after Osimertinib and ALK mutations in 4/7 (57%) at TKI failure, with a total of 50% (21/42) cases where ctDNA provided clinical utility. Conclusions ctDNA proved clinically informative results for 33% in untreated patients, most of them ESCAT tier I GA (22%) directing targeted therapies in routine. At time of TKI failure, ctDNA was clinically informative assessing resistance in 50% of EGFR/ALK patients. Legal entity responsible for the study Gustave Roussy. Funding Has not received any funding. Disclosure L. Mezquita: Advisory / Consultancy: Roche Diagnostics; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Tecnofarma; Honoraria (self): Roche; Honoraria (self): AstraZeneca; Travel / Accommodation / Expenses: Chugai. D. Planchard: Advisory / Consultancy: Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Research grant / Funding (institution): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo; Travel / Accommodation / Expenses: AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer; Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche. F. de Kievit: Shareholder / Stockholder / Stock options: INIVATA Ltd. L. Lacroix: Advisory / Consultancy: Abbott, Astrazeneca, Boehringer Ingelheim, Bristol Myers Squibb, Ca Bayer Healthcarer, Illumina, Genomic Health, Myriad, Novartis, Pfizer, Roche, Siemens, Thermofisher, VelaDx. J. Remon Masip: Advisory / Consultancy: Pfizer, MSD, BMS, Astrazeneca, Boehringer Ingelheim; Travel / Accommodation / Expenses: OSE Immunotherapeutics, BMS, Astrazeneca, Roche; Honoraria (self): OSE Immunotherapeutics. P. Lavaud: Travel / Accommodation / Expenses: Astellas-Pharma, AstraZeneca, Ipsen, Janssen Oncology, Mundi Pharma. A. Gazzah: Travel / Accommodation / Expenses: Boehringer Ingelheim, Novartis, Pfizer, Roche; Advisory / Consultancy: Novartis; Research grant / Funding (institution), Clinical trials at Gustave Roussy: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Bristol; Research grant / Funding (institution): AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; Non-remunerated activity/ies, Drug supply: Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. C. Morris: Shareholder / Stockholder / Stock options: INIVATA Ltd. K. Howarth: Shareholder / Stockholder / Stock options: INIVATA Ltd. E. Green: Shareholder / Stockholder / Stock options: INIVATA Ltd. C. Massard: Advisory / Consultancy: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion; Research grant / Funding (institution), Clinical Trials at Gustave Roussy: AbbVie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boehringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomed. B. Besse: Research grant / Funding (institution): AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma; Research grant / Funding (institution), Clinical Trials at Gustave Roussy: Nerviano, GSK, Pfizer, Roche-Genentech, Lilly, OSE Pharma, MSD, Celgene, Stemcentrx, Ignyta, AbbVie, Loxo Oncology, AstraZeneca, Blueprint Medicines. All other authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
249. 26P A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs).
- Author
-
Enrico, D H, Lacroix, L, Rouleau, E, Scoazec, J-Y, Loriot, Y, Tselikas, L, Jovelet, C, Planchard, D, Gazzah, A, Mezquita, L, Ngo, M, Michiels, S, Maillard, A, Massard, C, Facchinetti, F, Soria, J-C, André, F, Vassal, G, Friboulet, L, and Besse, B
- Subjects
- *
NON-small-cell lung carcinoma , *PROTEIN-tyrosine kinases , *COMPARATIVE genomic hybridization , *KINASE inhibitors , *EPIDERMAL growth factor receptors - Abstract
Background Despite a primary benefit, almost all patients (pts) develop acquired resistance to EGFR TKIs. Some mechanisms were related to the selective pressure of the different generations (G) EGFR TKIs, but the complete alteration profile at resistance remains to be elucidated. Methods Metastatic NSCLC pts who performed a tissue and plasma biopsy at EGFR TKI progression, and optionally before, were identified from the prospective MATCH-R trial (NCT02517892). Targeted next-generation sequencing (NGS, 74 to 82 genes), comparative genomic hybridization (CGH), whole-exome sequencing (WES), and RNA sequencing (RNA-Seq) were performed on the tissue. All molecular oncogenic alterations were classified as definitive/potential resistance mechanism or concomitant genetic alterations using OncoKB and Cancer Genome Interpreter. Results Among 62 pts included, tissue analysis at TKI progression was successful with NGS (94%), CGH (76%) and WES+RNA-Seq (53%). In the post 1st-2nd G EGFR TKI cohort (31 pts) the most frequent resistance alteration was p.T790M (n = 23, 74%). EGFR amplification (amp) was found in 7 (23%) pts and off-target mutations (mut) at resistance in 9 (29%, 2 KRAS, 2 JAK2, 1 PIK3CA, and 1 MET). Median PFS to EGFR TKI was 17 months (mo) for the pts with p.T790M as the only resistance mechanism vs 8 mo for the other resistance profiles (HR 2.42 [95% CI, 1.04-5.65]; p = 0.028). In the post 3rd G cohort (31 pts), acquired resistance alterations were mostly on-target (n = 12, 39%): 9 p.C797S, 2 p.L718Q and 1 EGFR amp. Off-target resistance alterations were found in 11 (35%) tumors: 5 fusions involving oncogenes (16%, RET, BRAF, ALK, and FGFR3), 2 BRAF p.V600E (6%), then MET amp, HER2 amp, KRAS mut, and PIK3CA mut in 1 pts (3%). p.T790M loss (54%) was associated with a shorter time to osimertinib discontinuation vs maintained (median 13 vs 22 mo; HR 2.16 (95% CI, 1.00-4.73); p = 0.046). More than one resistance mechanism was found in 12 (39%) and 14 (45%) pts in the post 1st-2nd and 3rd G cohort, respectively. Conclusions Genetic alteration landscape at EGFR TKIs progression is complex and heterogeneous since more than one resistance alteration was recognized in 42% of pts. Combination strategy might be needed. Legal entity responsible for the study Gustave Roussy, Cancer Campus. Funding Gustave Roussy, Cancer Campus. Disclosure Y. Loriot: Honoraria (self): Roche, MSD, Astellas, Janssen, AstraZeneca, BMS, Seattle Genetics, Sanofi, Clovis, Pfizer; Honoraria (institution): Roche, MSD, Astellas, Janssen, AstraZeneca, BMS, Seattle Genetics, Sanofi, Clovis, Incyte, Pfizer; Research grant / Funding (institution): Roche, MSD, Sanofi; Travel / Accommodation / Expenses: Roche, MSD, Janssen, AstraZeneca, Seattle Genetics; Licensing / Royalties: Pending patent (USA 62/455211, Europe 17209098.7). D. Planchard: Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, MedImmune, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Research grant / Funding (institution): AstraZeneca, Bristol-Myers Squibb, AbbVie, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, MedImmune, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo; Travel / Accommodation / Expenses: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim , Roche, Merck, Novartis, prIME Oncology, Pfizer. S. Michiels: Advisory / Consultancy, Punctual statistical advice : IDDI Belgium, Janssen Cilag France; Advisory / Consultancy, Data and Safety Monitoring Member: Hexal, J&J, Ipsen, Neovacs, Genticel, Mabxience, Steba, IQVIA, Roche, Sensorion, Biophytis. C. Massard: Advisory / Consultancy: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Novartis, Pfizer, Roche, Sanofi, Orion; Principal/sub-Investigator of Clinical Trials for AbbVie, Agios Pharmaceuticals, Amgen, Argen-X; Research grant / Funding (institution): AstraZeneca, BMS, Boehringer Ingelheim, Janssen-Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; Non-remunerated activity/ies: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuiX, Pfizer, Roche. J-C. Soria: Advisory / Consultancy: AstraZeneca, Astex, Clovis, GSK, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen, and Takeda; Full / Part-time employment: AstraZeneca; Shareholder / Stockholder / Stock options: AstraZeneca and Gritstone. F. André: Research grant / Funding (institution): NVS, AZ, Roche, Daiichi, Lilly, Pfizer. G. Vassal: Advisory / Consultancy, Non-remunerated activity/ies: AstraZeneca, Bayer, BMS, Celgene, Incyte, Ipsen, Lilly, MSD, Merck, Pierre-Fabre, Novartis, Pfizer, Roche/Genentech, Servier, Takeda. B. Besse: Research grant / Funding (institution): AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma. All other authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
250. New policies to address the global burden of childhood cancers
- Author
-
Ian Magrath, Gilles Vassal, Scott C. Howard, Ruth Ladenstein, Edel Fitzgerald, Ronald D. Barr, Maria Grazia Valsecchi, Peter C. Adamson, Jerzy Kowalczyk, Paul E. Grundy, Mariana Kruger, Richard Sullivan, Bharat Agarwal, Kathy Pritchard-Jones, Malcolm A. Smith, Eva Steliarova-Foucher, Andrea Biondi, Sullivan, R, Kowalczyk, J, Agarwal, B, Ladenstein, R, Fitzgerald, E, Barr, R, Steliarova Foucher, E, Magrath, I, Howard, S, Kruger, M, Valsecchi, M, Biondi, A, Grundy, P, Smith, M, Adamson, P, Vassal, G, and Pritchard Jones, K
- Subjects
Economic growth ,medicine.medical_specialty ,Civil society ,Adolescent ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,030225 pediatrics ,Global health ,Remuneration ,Humans ,Medicine ,Child ,Clinical Trials as Topic ,Childhood, cancer ,Government ,business.industry ,Developed Countries ,Health Policy ,Research ,Public health ,Environmental resource management ,1. No poverty ,Millennium Development Goals ,3. Good health ,Clinical trial ,Oncology ,030220 oncology & carcinogenesis ,business ,Career development - Abstract
Childhood cancer is a major global health issue. Every year, almost 100 000 children die from cancer before the age of 15 years, more than 90% of them in resource-limited countries. Here, we review the key policy issues for the delivery of better care, research, and education of professionals and patients. We present a key list of time-limited proposals focusing on change to health systems and research and development. These include sector and system reforms to make care affordable to all, policies to promote growth of civil society around both cancer and Millennium Development Goals, major improvements to public health services (particularly the introduction of national cancer plans), improved career development, and increased remuneration of specialist health-care workers and government support for childhood cancer registries. Research and development proposals focus on sustainable funding, the establishment of more research networks, and clinical research specifically targeted at the needs of low-income and middle-income countries. Finally, we present proposals to address the need for clinical trial innovation, the complex dichotomy of regulations, and the threats to the availability of data for childhood cancers. © 2013 Elsevier Ltd.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.